BRCA1 and breast cancer: RANKL inhibitors such as denosumab may be combined with hormone modulators such as progesterone antagonists or even inhibitors of RANK signaling, which may reduce mammary epithelial proliferation and counteract the elevated breast cancer development risk involved in BRCA1 mutation carriers [67].